{"id":"dopamine-hydrochloride","_fda":{"id":"7e96af3b-9be0-46ec-92e6-976d6e1ea57d","set_id":"08f23f6e-150d-45ea-098e-f2edf64c21a1","openfda":{"unii":["7L3E358N9L"],"route":["INTRAVENOUS"],"rxcui":["1292887","1743877","1743879"],"spl_id":["7e96af3b-9be0-46ec-92e6-976d6e1ea57d"],"brand_name":["Dopamine Hydrochloride in Dextrose"],"spl_set_id":["08f23f6e-150d-45ea-098e-f2edf64c21a1"],"package_ndc":["0409-7809-11","0409-7809-22","0409-7809-31","0409-7809-24","0409-7810-11","0409-7810-22","0409-0042-01","0409-0042-12","0409-1858-01","0409-1858-12"],"product_ndc":["0409-0042","0409-7809","0409-7810","0409-1858"],"generic_name":["DOPAMINE HYDROCHLORIDE IN DEXTROSE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DOPAMINE HYDROCHLORIDE"],"manufacturer_name":["Hospira, Inc."],"application_number":["NDA018826"],"is_original_packager":[true]},"version":"26","pregnancy":["8.1 Pregnancy Risk Summary There are no human data with dopamine use in pregnant women. There are risks to the mother and fetus from hypotension associated with shock, which can be fatal if left untreated ( see Clinical Considerations ). In animal reproduction studies, adverse developmental outcomes were observed with intravenous dopamine HCl administration in pregnant rats during organogenesis at dosages, on a mcg/m 2 basis, of one-third the human starting dosage of 2 mcg/kg/minute (90 mcg/m 2 /minute). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies carry some risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypotension associated with distributive shock, or shock due to reduced cardiac output are medical emergencies in pregnancy which can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with distributive shock, or shock due to reduced cardiac output may increase the risk of maternal and fetal morbidity and mortality. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of dopamine on the fetus. Labor or Delivery Vasopressor drugs, including dopamine, may cause severe maternal hypertension when used concomitantly with some oxytocic drugs [see Drug Interactions (7) ] . Data Animal Data Animal reproduction studies in rats and rabbits at dopamine HCl dosages up to 6 mg/kg/day intravenously (on a mcg/m 2 basis, one-third and two-thirds, respectively, the human starting dosage of 2 mcg/kg/minute) during organogenesis produced no detectable teratogenic or embryotoxic effects, although maternal toxicity consisting of mortalities, decreased body weight gain, and pharmacotoxic signs were observed in rats. In a published study, administration of 10 mg/kg/day dopamine HCl (on a mcg/m 2 basis, two-thirds the human starting dosage of 2 mcg/kg/minute) to pregnant rats throughout gestation or for 5 days starting on gestation day 10 or 15 resulted in decreased body weight gain, increased mortality, and slight increase in cataract formation among the offspring."],"overdosage":["10 OVERDOSAGE Manifestations of overdosage include excessive blood pressure elevation. In the case of accidental overdosage, reduce rate of Dopamine HCl in Dextrose Injection infusion, or temporarily discontinue the Dopamine HCl in Dextrose Injection infusion until the overdosage related adverse reactions resolves. Since dopamine's duration of action is short, no additional remedial measures are usually necessary. If these measures fail to resolve the overdosage related adverse reactions, consider using an alpha-adrenergic blocking agent (e.g., phentolamine)."],"description":["11 DESCRIPTION Dopamine Hydrochloride in 5% Dextrose Injection, USP is a sterile, nonpyrogenic, premixed solution of dopamine hydrochloride in 5% dextrose injection for intravenous infusion. Each 100 mL contains 160 mg (1,600 mcg/mL) or 320 mg (3,200 mcg/mL) of dopamine HCl; 5 grams of hydrous dextrose, in Water for Injection, and 50 mg of sodium metabisulfite (a stabilizer); pH = 2.5 to 4.5, and the following osmolar concentrations: 269, or 286 mOsmol/liter, respectively. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. Dopamine HCl is chemically designated 3, 4-dihydroxyphenethylamine hydrochloride (C 8 H 11 NO 2 ∙ HCl), a white crystalline powder freely soluble in water. Dopamine HCl has a molecular weight of 189.64 and it has the following structural formula: Dopamine (also referred to as 3-hydroxytyramine) is a naturally occurring endogenous catecholamine. Dextrose, USP is chemically designated D-glucose monohydrate (C 6 H 12 O 6 ∙ H 2 O), a hexose sugar freely soluble in water. The molecular weight of dextrose (D-glucose) monohydrate is 198.17 and it has the following structural formula: Water for Injection, USP is chemically designated H 2 O. Chemical Structure Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Dopamine Hydrochloride in 5% Dextrose Injection, USP, is supplied in 250 and 500 mL single-dose flexible plastic containers (the solutions are clear to slightly yellow in appearance) as follows. Each 100 mL contains 5 grams of hydrous dextrose in Water for Injection. Unit of Sale Total Strength/Total Volume (Concentration) NDC 0409-7809-22 Case of 12 single-dose flexible containers 400 mg/250 mL (1,600 mcg/mL) NDC 0409-0042-12 Case of 12 single-dose flexible containers 400 mg/250 mL (1,600 mcg/mL) NDC 0409-7809-24 Case of 12 single-dose flexible containers 800 mg/500 mL (1,600 mcg/mL) NDC 0409-7810-22 Case of 12 single-dose flexible containers 800 mg/250 mL (3,200 mcg/mL) NDC 0409-1858-12 Case of 12 single-dose flexible containers 800 mg/250 mL (3,200 mcg/mL) Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Discard unused portion."],"geriatric_use":["8.5 Geriatric Use Clinical studies of dopamine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should start at the low end of the dosing range, reflecting the frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["8.4 Pediatric Use Dopamine HCl infusions have been used in pediatric patients from birth through adolescence. Most reports in pediatric patients describe dosing that is similar (on a mcg/kg/minute basis) to that used in adults [see Dosage and Administration (2.2) ] . Except for vasoconstrictive effects caused by inadvertent infusion of dopamine into the umbilical artery, adverse reactions unique to pediatric patients have not been identified, nor have adverse reactions identified in adults been found to be more common in pediatric patients."],"effective_time":"20251103","pharmacodynamics":["12.2 Pharmacodynamics Dopamine's onset of action occurs within five minutes of intravenous administration and the duration of action is less than about ten minutes. Dopamine effects are dosage-dependent. • At <5 mcg/kg/minute, dopamine HCl activates dopamine D1 and D2 receptors in the renal, mesenteric, and coronary vasculature causing vasodilation. • At 5 to 10 mcg/kg/minute, dopamine HCl activates beta-1 receptors enhancing heart rate and contractility. • At >10 mcg/kg/minute, dopamine HCl activates alpha-1 receptors causing vasoconstriction and increased blood pressure"],"pharmacokinetics":["12.3 Pharmacokinetics Distribution Following intravenous administration, dopamine is widely distributed in the body but does not cross the blood-brain barrier to a significant extent. Elimination The half-life of dopamine in adults is less than 2 minutes. Metabolism About 75% of dopamine is metabolized by monoamine oxidase (MAO) and catechol O-methyl transferase (COMT) in the liver, kidney, and plasma to the inactive compounds homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid, and about 25% is metabolized to norepinephrine in the adrenergic nerve terminals. Excretion About 80% of dopamine is renally excreted as inactive metabolites within 24 hours. Dopamine is stored in vesicles or diffused back into the plasma. Specific Populations Pediatric Patients The reported clearance rate of dopamine in critically ill infants and pediatric patients ranged from 46 to 168 mL/kg/minute, with the higher values seen in the younger patients. The reported apparent volume of distribution in neonates was 0.6 to 4 L/kg, leading to an elimination half-life of 5 to 11 minutes."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are described elsewhere in the labeling: • Tissue Ischemia [see Warnings and Precautions (5.1) ] • Cardiac Arrhythmias [see Warnings and Precautions (5.2) ] • Hypotension [see Warnings and Precautions (5.3) ] • Severe Hypersensitivity Reactions [see Warnings and Precautions (5.4) ] The following adverse reactions have been identified during post-approval use of dopamine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiac Disorders : anginal pain, palpitation Gastrointestinal Disorders : nausea, vomiting Metabolism and Nutrition Disorders : azotemia Nervous System Disorders : headache, anxiety Respiratory Disorders : dyspnea Skin and Subcutaneous Tissue Disorders : piloerection Vascular Disorders : hypertension The most common adverse reaction is localized vasoconstriction due to extravasation. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ."],"contraindications":["4 CONTRAINDICATIONS Dopamine is contraindicated in patients with pheochromocytoma. Patients with pheochromocytoma. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS See Table 1 for clinically significant drug interactions with dopamine. Table 1: Clinically Significant Drug Interactions with Dopamine Halogenated Anesthetics Clinical Impact: Concomitant use may increase cardiac autonomic irritability and can sensitize the myocardium to the action of dopamine which may lead to ventricular arrhythmias and hypertension. Intervention: Monitor cardiac rhythm. Examples: desflurane, enflurane, isoflurane, and sevoflurane. MAO Inhibitors Clinical Impact: Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine which may result in severe hypertension and cardiac arrhythmia. Intervention: Reduce the recommended starting dosage to no greater than one-tenth (1/10) of the recommended dose in patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of Dopamine HCl in Dextrose Injection. Examples: isocarboxazid, phenelzine, tranylcypromine, rasagiline, selegiline, linezolid. Tricyclic Antidepressants Clinical Impact: Concomitant use may potentiate the cardiovascular effects of dopamine (e.g., hypertension). Intervention: Monitor blood pressure. Examples: amitriptyline, desipramine, doxepin, imipramine, nortriptyline. Vasopressors Clinical Impact: Concomitant use may result in severe hypertension. Intervention: Monitor blood pressure. Examples: norepinephrine, epinephrine, oxytocin. • Halogenated anesthetics : Can sensitize the myocardium to the effects of dopamine and can produce ventricular arrhythmias and hypertension. ( 7 ) • MAO inhibitors : Risk of severe hypertension. Reduce recommended Dopamine HCl in Dextrose Injection dosage. ( 7 ) • Tricyclic antidepressants : Risk of hypertension. Monitor blood pressure. ( 7 ) • Vasopressors : Risk of severe hypertension. Monitor blood pressure. ( 7 )"],"how_supplied_table":["
Unit of SaleTotal Strength/Total Volume (Concentration)
NDC 0409-7809-22 Case of 12 single-dose flexible containers400 mg/250 mL (1,600 mcg/mL)
NDC 0409-0042-12 Case of 12 single-dose flexible containers400 mg/250 mL (1,600 mcg/mL)
NDC 0409-7809-24 Case of 12 single-dose flexible containers800 mg/500 mL (1,600 mcg/mL)
NDC 0409-7810-22 Case of 12 single-dose flexible containers800 mg/250 mL (3,200 mcg/mL)
NDC 0409-1858-12 Case of 12 single-dose flexible containers800 mg/250 mL (3,200 mcg/mL)
"],"mechanism_of_action":["12.1 Mechanism of Action Dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal tract, and in a few peripheral sympathetic nerves. Dopamine elicits its pharmacological action by activating dopamine D1 and D2 receptors, beta-1 receptors and alpha-1 receptors. The activation of different receptors leading to its effects are dependent on dopamine dose."],"storage_and_handling":["Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Discard unused portion."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal tract, and in a few peripheral sympathetic nerves. Dopamine elicits its pharmacological action by activating dopamine D1 and D2 receptors, beta-1 receptors and alpha-1 receptors. The activation of different receptors leading to its effects are dependent on dopamine dose. 12.2 Pharmacodynamics Dopamine's onset of action occurs within five minutes of intravenous administration and the duration of action is less than about ten minutes. Dopamine effects are dosage-dependent. • At <5 mcg/kg/minute, dopamine HCl activates dopamine D1 and D2 receptors in the renal, mesenteric, and coronary vasculature causing vasodilation. • At 5 to 10 mcg/kg/minute, dopamine HCl activates beta-1 receptors enhancing heart rate and contractility. • At >10 mcg/kg/minute, dopamine HCl activates alpha-1 receptors causing vasoconstriction and increased blood pressure 12.3 Pharmacokinetics Distribution Following intravenous administration, dopamine is widely distributed in the body but does not cross the blood-brain barrier to a significant extent. Elimination The half-life of dopamine in adults is less than 2 minutes. Metabolism About 75% of dopamine is metabolized by monoamine oxidase (MAO) and catechol O-methyl transferase (COMT) in the liver, kidney, and plasma to the inactive compounds homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid, and about 25% is metabolized to norepinephrine in the adrenergic nerve terminals. Excretion About 80% of dopamine is renally excreted as inactive metabolites within 24 hours. Dopamine is stored in vesicles or diffused back into the plasma. Specific Populations Pediatric Patients The reported clearance rate of dopamine in critically ill infants and pediatric patients ranged from 46 to 168 mL/kg/minute, with the higher values seen in the younger patients. The reported apparent volume of distribution in neonates was 0.6 to 4 L/kg, leading to an elimination half-life of 5 to 11 minutes."],"indications_and_usage":["1 INDICATIONS AND USAGE Dopamine Hydrochloride in Dextrose Injection is indicated to improve hemodynamic status in patients in distributive shock, or shock due to reduced cardiac output. Dopamine HCl in Dextrose Injection is a catecholamine indicated to improve hemodynamic status in patients in shock. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Tissue ischemia : Severe peripheral and visceral vasoconstriction can occur. Address hypovolemia prior to use, monitor extremities, and infuse into large vein. ( 5.1 ) • Cardiac arrhythmias : Monitor closely. ( 5.2 ) • Hypotension after abrupt discontinuation : Gradually reduce infusion rate while expanding blood volume with intravenous fluids. ( 5.3 ) • Severe hypersensitivity reactions due to sodium metabisulfite excipient : May cause anaphylaxis including life-threatening or less severe asthmatic episodes in susceptible individuals. ( 5.4 ) 5.1 Tissue Ischemia Administration of dopamine to patients who are hypotensive from hypovolemia can result in severe peripheral and visceral vasoconstriction, decreased renal perfusion and hypouresis, tissue hypoxia, lactic acidosis, and poor systemic blood flow despite \"normal\" blood pressure. Address hypovolemia prior to initiating Dopamine HCl in Dextrose Injection [see Dosage and Administration (2.2) ] . Gangrene of the extremities has occurred in patients with occlusive vascular disease or who received prolonged or high dose infusions. Monitor for changes to the skin of the extremities in susceptible patients. Extravasation of Dopamine HCl in Dextrose Injection may cause necrosis and sloughing of surrounding tissue. To reduce the risk of extravasation, infuse into a large vein [see Dosage and Administration (2.1) ] , check the infusion site frequently for free flow, and monitor for signs of extravasation. Emergency Treatment of Extravasation To prevent sloughing and necrosis in areas in which extravasation has occurred, infiltrate the ischemic area as soon as possible, using a syringe with a fine hypodermic needle with: • 5 to 10 mg of phentolamine mesylate in 10 to 15 mL of 0.9% Sodium Chloride Injection in adults • 0.1 to 0.2 mg/kg of phentolamine mesylate up to a maximum of 10 mg per dose in pediatric patients. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours. 5.2 Cardiac Arrhythmias Dopamine may cause arrhythmias. Monitor patients with arrhythmias and treat appropriately. 5.3 Hypotension after Abrupt Discontinuation Sudden cessation of the infusion rate may result in marked hypotension. Gradually reduce the infusion rate while expanding blood volume with intravenous fluids. 5.4 Severe Hypersensitivity Reactions due to Sodium Metabisulfite Excipient Dopamine HCl in Dextrose Injection, contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Long term animal studies have not been performed to evaluate the carcinogenic potential of dopamine. Mutagenesis Dopamine HCl at doses approaching maximal solubility showed no clear genotoxic potential in the Ames test. Although there was a reproducible dose-dependent increase in the number of revertant colonies with strains TA100 and TA98, both with and without metabolic activation, the small increase was considered inconclusive evidence of mutagenicity. In the L5178Y TK +/- mouse lymphoma assay, dopamine HCl at the highest concentrations used of 750 mcg/mL without metabolic activation, and 3,000 mcg/mL with activation, was toxic and associated with increases in mutant frequencies when compared to untreated and solvent controls; at the lower concentrations no increases over controls were noted. No clear evidence of clastogenic potential was reported in the in vivo mouse or male rat bone marrow micronucleus test when the animals were treated intravenously with up to 224 mg/kg and 30 mg/kg of dopamine HCl, respectively."],"drug_interactions_table":["
Table 1: Clinically Significant Drug Interactions with Dopamine
Halogenated Anesthetics
Clinical Impact:Concomitant use may increase cardiac autonomic irritability and can sensitize the myocardium to the action of dopamine which may lead to ventricular arrhythmias and hypertension.
Intervention:Monitor cardiac rhythm.
Examples:desflurane, enflurane, isoflurane, and sevoflurane.
MAO Inhibitors
Clinical Impact:Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine which may result in severe hypertension and cardiac arrhythmia.
Intervention:Reduce the recommended starting dosage to no greater than one-tenth (1/10) of the recommended dose in patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of Dopamine HCl in Dextrose Injection.
Examples:isocarboxazid, phenelzine, tranylcypromine, rasagiline, selegiline, linezolid.
Tricyclic Antidepressants
Clinical Impact:Concomitant use may potentiate the cardiovascular effects of dopamine (e.g., hypertension).
Intervention:Monitor blood pressure.
Examples:amitriptyline, desipramine, doxepin, imipramine, nortriptyline.
Vasopressors
Clinical Impact:Concomitant use may result in severe hypertension.
Intervention:Monitor blood pressure.
Examples:norepinephrine, epinephrine, oxytocin.
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Risk of Tissue Damage Advise the patient, family, or caregiver to report signs of extravasation urgently [see Warnings and Precautions (5.1) ]."],"spl_unclassified_section":["Distributed by Hospira, Inc., Lake Forest, IL 60045 USA LAB-1153-5.0 Logo"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • Correct hypovolemia, acidosis, and hypoxia prior to use. ( 2.1 ) • Administer in a large vein with an infusion pump preferably in an intensive care setting. ( 2.1 ) • Recommended starting dosage in adults and pediatric patients is 2 to 5 mcg/kg/minute as a continuous intravenous infusion. Titrate in 5 to 10 mcg/kg/minute increments based on hemodynamic response and tolerability, up to not more than 50 mcg/kg/minute. ( 2.2 ) • See the Full Prescribing Information for important preparation instructions and drug incompatibilities. ( 2.3 ) 2.1 Administration Instructions Correct Hypovolemia, Acidosis, and Hypoxia Address hypovolemia, acidosis, and hypoxia before initiating Dopamine HCl in Dextrose Injection. If patient does not respond to therapy, suspect occult hypovolemia. Acidosis may reduce the effectiveness of dopamine [see Warnings and Precautions (5.1) ] . Administration Dopamine HCl in Dextrose Injection is a premixed infusion solution that does not require dilution prior to intravenous administration. Administer Dopamine HCl in Dextrose Injection into a large vein [see Warnings and Precautions (5.1) ] with the use of an infusion pump preferably in an intensive care setting. Remove outer wrap (moisture and oxygen barrier) only when ready to administer the product. Discard product if outer wrap is damaged (e.g., tears or holes). Inspect Dopamine HCl in Dextrose Injection for particulate matter and discoloration prior to administration (the solution is clear to slightly yellow). Do not administer if the solution is darker than slightly yellow or the container is damaged. Use higher concentration premixed solutions (e.g., 3,200 mcg/mL or 1,600 mcg/mL strengths) in patients requiring fluid restriction. Discontinuation When discontinuing Dopamine HCl in Dextrose Injection, gradually reduce the infusion rate while expanding blood volume with intravenous fluids [see Warnings and Precautions (5.3) ]. 2.2 Recommended Dosage The recommended starting dosage in adults and pediatric patients is 2 to 5 mcg/kg/minute as a continuous intravenous infusion [see Dosage and Administration (2.3) ] . Titrate the infusion rate in 5 to 10 mcg/kg/minute increments based on hemodynamic response and tolerability, up to but not more than 50 mcg/kg/minute. Infusion rates may be calculated using the following formula: Infusion Rate (mL/hour) = [Dose (mcg/kg/minute) × Weight (kg) × 60 (minutes/hour)] Concentration (mcg/mL) Example calculations for infusion rates are as follows: Example 1: for a 60 kg person at the recommended initial dose of 2 mcg/kg/minute using a 1,600 mcg/mL concentration, the infusion rate would be as follows: Infusion Rate (mL/hour) = [2 (mcg/kg/minute) × 60 (kg) × 60 (minutes/hour) ] = 4.5 (mL/hour) 1,600 (mcg/mL) Example 2: for a 70 kg person at a dose of 5 mcg/kg/minute using a 3,200 mcg/mL concentration, the infusion rate would be as follows: Infusion Rate (mL/hour) = [5 (mcg/kg/minute) × 70 (kg) × 60 (minutes/hour) ] = 6.56 (mL/hour) 3,200 (mcg/mL) 2.3 Drug Incompatibilities Dopamine HCl in Dextrose Injection is incompatible with the following products; therefore, avoid simultaneous administration (through the same infusion set): • Sodium bicarbonate or other alkalinizing substances, because dopamine is inactivated in alkaline solution. • Blood, because of the risk of pseudoagglutination of red cells • Iron salts Do not add additional medications in the premixed infusion solution."],"spl_product_data_elements":["Dopamine Hydrochloride in Dextrose Dopamine Hydrochloride in Dextrose DOPAMINE HYDROCHLORIDE DOPAMINE WATER HYDROCHLORIC ACID SODIUM HYDROXIDE DEXTROSE MONOHYDRATE SODIUM METABISULFITE Dopamine Hydrochloride in Dextrose Dopamine Hydrochloride in Dextrose DOPAMINE HYDROCHLORIDE DOPAMINE DEXTROSE MONOHYDRATE WATER SODIUM METABISULFITE HYDROCHLORIC ACID SODIUM HYDROXIDE Dopamine Hydrochloride in Dextrose Dopamine Hydrochloride in Dextrose DOPAMINE HYDROCHLORIDE DOPAMINE DEXTROSE MONOHYDRATE WATER SODIUM METABISULFITE HYDROCHLORIC ACID SODIUM HYDROXIDE Dopamine Hydrochloride in Dextrose Dopamine Hydrochloride in Dextrose DOPAMINE HYDROCHLORIDE DOPAMINE DEXTROSE MONOHYDRATE WATER SODIUM METABISULFITE HYDROCHLORIC ACID SODIUM HYDROXIDE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS The following strengths of Dopamine Hydrochloride in 5% Dextrose Injection, USP, are supplied in single-dose flexible plastic containers (the solutions are clear to slightly yellow in appearance): • 1,600 mcg/mL (250 or 500 mL) • 3,200 mcg/mL (250 mL) Each 100 mL contains 5 grams of hydrous dextrose in Water for Injection. Following strengths of Dopamine Hydrochloride in 5% Dextrose Injection, USP, are supplied in single-dose flexible plastic containers (each 100 mL contains 5 grams of hydrous dextrose in Water for Injection): ( 3 ) • 1,600 mcg/mL (250 and 500 mL) • 3,200 mcg/mL (250 mL)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no human data with dopamine use in pregnant women. There are risks to the mother and fetus from hypotension associated with shock, which can be fatal if left untreated ( see Clinical Considerations ). In animal reproduction studies, adverse developmental outcomes were observed with intravenous dopamine HCl administration in pregnant rats during organogenesis at dosages, on a mcg/m 2 basis, of one-third the human starting dosage of 2 mcg/kg/minute (90 mcg/m 2 /minute). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies carry some risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypotension associated with distributive shock, or shock due to reduced cardiac output are medical emergencies in pregnancy which can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with distributive shock, or shock due to reduced cardiac output may increase the risk of maternal and fetal morbidity and mortality. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of dopamine on the fetus. Labor or Delivery Vasopressor drugs, including dopamine, may cause severe maternal hypertension when used concomitantly with some oxytocic drugs [see Drug Interactions (7) ] . Data Animal Data Animal reproduction studies in rats and rabbits at dopamine HCl dosages up to 6 mg/kg/day intravenously (on a mcg/m 2 basis, one-third and two-thirds, respectively, the human starting dosage of 2 mcg/kg/minute) during organogenesis produced no detectable teratogenic or embryotoxic effects, although maternal toxicity consisting of mortalities, decreased body weight gain, and pharmacotoxic signs were observed in rats. In a published study, administration of 10 mg/kg/day dopamine HCl (on a mcg/m 2 basis, two-thirds the human starting dosage of 2 mcg/kg/minute) to pregnant rats throughout gestation or for 5 days starting on gestation day 10 or 15 resulted in decreased body weight gain, increased mortality, and slight increase in cataract formation among the offspring. 8.2 Lactation Risk Summary There are no data regarding the presence of dopamine in human milk, the effects of dopamine on the breastfed infant, or the effects of the drug on milk production. 8.4 Pediatric Use Dopamine HCl infusions have been used in pediatric patients from birth through adolescence. Most reports in pediatric patients describe dosing that is similar (on a mcg/kg/minute basis) to that used in adults [see Dosage and Administration (2.2) ] . Except for vasoconstrictive effects caused by inadvertent infusion of dopamine into the umbilical artery, adverse reactions unique to pediatric patients have not been identified, nor have adverse reactions identified in adults been found to be more common in pediatric patients. 8.5 Geriatric Use Clinical studies of dopamine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should start at the low end of the dosing range, reflecting the frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy."],"dosage_and_administration_table":["
Infusion Rate (mL/hour) = [Dose (mcg/kg/minute) × Weight (kg) × 60 (minutes/hour)] Concentration (mcg/mL)
","
Infusion Rate (mL/hour) =[2 (mcg/kg/minute) × 60 (kg) × 60 (minutes/hour)] = 4.5 (mL/hour)
1,600 (mcg/mL)
","
Infusion Rate (mL/hour) =[5 (mcg/kg/minute) × 70 (kg) × 60 (minutes/hour)] = 6.56 (mL/hour)
3,200 (mcg/mL)
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - WR-1540 TO OPEN — TEAR AT NOTCH Each 100 mL contains dopamine hydrochloride 160 mg; dextrose, hydrous 5 g in water for injection; sodium metabisulfite added 50 mg. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. 269 mOsmol/liter (calc.) ph 3.8 (2.5 to 4.5). Single-dose container. Discard unused portion. For intravenous use. Usual dosage: see insert. WARNING: CONTAINS SULFITES. Drug additives should not be made to this solution. The overwrap is a moisture and oxygen barrier. Do not remove unit from overwrap until ready for use. Visually inspect overwrap for tears or holes. Discard unit if overwrap is damaged or if solution is darker than slightly yellow or discolored in any other way. Use unit promptly when overwrap is opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. See insert. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. Rx only 250 mL NDC 0409-7809-11 DOPAMINE HCl in 5% Dextrose Injection, USP 400 mg/250 mL (1,600 mcg/mL) Single-dose container F WR-1540 Distributed by Hospira, Inc., Lake Forest, IL 60045 USA Hospira PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - WR-1540","PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - IM-4355 250 mL NDC 0409-7809-11 DOPAMINE HCl in 5% Dextrose Injection, USP 400 mg/250 mL (1,600 mcg/mL) EACH 100 mL CONTAINS DOPAMINE HYDROCHLORIDE 160 mg; DEXTROSE, HYDROUS 5 g IN WATER FOR INJECTION; SODIUM METABISULFITE ADDED 50 mg. MAY CONTAIN HYDROCHLORIC ACID AND/OR SODIUM HYDROXIDE FOR pH ADJUSTMENT. 269 mOsmol/LITER (CALC.) pH 3.8 (2.5 to 4.5). SINGLE-DOSE CONTAINER. DISCARD UNUSED PORTION. FOR INTRAVENOUS USE. USUAL DOSAGE: SEE INSERT. WARNING: CONTAINS SULFITES. DRUG ADDITIVES SHOULD NOT BE MADE TO THIS SOLUTION. STERILE NONPYROGENIC. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS. Rx ONLY 7 OTHER Hospira IM-4355 DISTRIBUTED BY HOSPIRA, INC., LAKE FOREST, IL 60045 USA PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - IM-4355","PRINCIPAL DISPLAY PANEL - 500 mL Bag Label - WR-1543 TO OPEN — TEAR AT NOTCH Each 100 mL contains dopamine hydrochloride 160 mg; dextrose, hydrous 5 g in water for injection; sodium metabisulfite added 50 mg. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. 269 mOsmol/liter (calc.) ph 3.8 (2.5 to 4.5). Single-dose container. Discard unused portion. For intravenous use. Usual dosage: see insert. WARNING: CONTAINS SULFITES. Drug additives should not be made to this solution. The overwrap is a moisture and oxygen barrier. Do not remove unit from overwrap until ready for use. Visually inspect overwrap for tears or holes. Discard unit if overwrap is damaged or if solution is darker than slightly yellow or discolored in any other way. Use unit promptly when overwrap is opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. See insert. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. Rx only 500 mL NDC 0409-7809-31 DOPAMINE HCl in 5% Dextrose Injection, USP 800 mg/500 mL (1,600 mcg/mL) Single-dose container F WR-1543 Distributed by Hospira, Inc., Lake Forest, IL 60045 USA Hospira PRINCIPAL DISPLAY PANEL - 500 mL Bag Label - WR-1543","PRINCIPAL DISPLAY PANEL - 500 mL Bag Label - IM-4356 500 mL NDC 0409-7809-31 DOPAMINE HCl in 5% Dextrose Injection, USP 800 mg/500 mL (1,600 mcg/mL) EACH 100 mL CONTAINS DOPAMINE HYDROCHLORIDE 160 mg; DEXTROSE, HYDROUS 5 g IN WATER FOR INJECTION; SODIUM METABISULFITE ADDED 50 mg. MAY CONTAIN HYDROCHLORIC ACID AND/OR SODIUM HYDROXIDE FOR pH ADJUSTMENT. 269 mOsmol/LITER (CALC.) pH 3.8 (2.5 to 4.5). SINGLE-DOSE CONTAINER. DISCARD UNUSED PORTION. FOR INTRAVENOUS USE. USUAL DOSAGE: SEE INSERT. WARNING: CONTAINS SULFITES. DRUG ADDITIVES SHOULD NOT BE MADE TO THIS SOLUTION. STERILE NONPYROGENIC. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS. Rx ONLY 7 OTHER Hospira IM-4356 DISTRIBUTED BY HOSPIRA, INC., LAKE FOREST, IL 60045 USA PRINCIPAL DISPLAY PANEL - 500 mL Bag Label - IM-4356","PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - WR-1544 TO OPEN — TEAR AT NOTCH Each 100 mL contains dopamine hydrochloride 320 mg; dextrose, hydrous 5 g in water for injection; sodium metabisulfite added 50 mg. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. 286 mOsmol/liter (calc.) ph 3.8 (2.5 to 4.5). Single-dose container. Discard unused portion. For intravenous use. Usual dosage: see insert. WARNING: CONTAINS SULFITES. Drug additives should not be made to this solution. The overwrap is a moisture and oxygen barrier. Do not remove unit from overwrap until ready for use. Visually inspect overwrap for tears or holes. Discard unit if overwrap is damaged or if solution is darker than slightly yellow or discolored in any other way. Use unit promptly when overwrap is opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. See insert. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. Rx only 250 mL NDC 0409-7810-11 DOPAMINE HCl in 5% Dextrose Injection, USP 800 mg/250 mL (3,200 mcg/mL) Single-dose container F WR-1544 Distributed by Hospira, Inc., Lake Forest, IL 60045 USA Hospira PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - WR-1544","PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - IM-4357 250 mL NDC 0409-7810-11 DOPAMINE HCl in 5% Dextrose Injection, USP 800 mg/250 mL (3,200 mcg/mL) EACH 100 mL CONTAINS DOPAMINE HYDROCHLORIDE 320 mg; DEXTROSE, HYDROUS 5 g IN WATER FOR INJECTION; SODIUM METABISULFITE ADDED 50 mg. MAY CONTAIN HYDROCHLORIC ACID AND/OR SODIUM HYDROXIDE FOR pH ADJUSTMENT. 286 mOsmol/LITER (CALC.) pH 3.8 (2.5 to 4.5). SINGLE- DOSE CONTAINER. DISCARD UNUSED PORTION. FOR INTRAVENOUS USE. USUAL DOSAGE: SEE INSERT. WARNING: CONTAINS SULFITES. DRUG ADDITIVES SHOULD NOT BE MADE TO THIS SOLUTION. STERILE NONPYROGENIC. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS. Rx ONLY 7 OTHER IM-4357 Hospira DISTRIBUTED BY HOSPIRA, INC., LAKE FOREST, IL 60045 USA PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - IM-4357","PRINCIPAL DISPLAY PANEL - 250 mL Bag Label -13444-01 TO OPEN — TEAR AT NOTCH Each 100 mL contains dopamine hydrochloride 160 mg; dextrose, hydrous 5 g in water for injection; sodium metabisulfite added 50 mg. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. 269 mOsmol/liter (calc.) pH 2.5 to 4.5 Single-dose container. Discard unused portion. For intravenous use only. Recommended Dosage: See Prescribing Information WARNING: CONTAINS SULFITES. Drug additives should not be made to this solution. The overwrap is a moisture and oxygen barrier. Do not remove unit from overwrap until ready for use. Visually inspect overwrap for tears or holes. Discard unit if overwrap is damaged or if solution is darker than slightly yellow or discolored in any other way. Use unit promptly when overwrap is opened. Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. Not made with natural rubber latex. Rx only 7 OTHER 250 mL NDC 0409-0042-01 DOPAMINE HCl in 5% Dextrose Injection, USP 400 mg/250 mL (1,600 mcg/mL) Single-dose container 13444-01 Hospira Distributed by Hospira, Inc., Lake Forest, IL 60045 USA PRINCIPAL DISPLAY PANEL - 250 mL Bag Label -13444-01","PRINCIPAL DISPLAY PANEL - 250 mL Bag Label-12726-02 250 mL NDC 0409-0042-01 DOPAMINE HCl in 5% Dextrose Injection, USP 400 mg/250 mL (1,600 mcg/mL) Each 100 mL contains dopamine hydrochloride 160 mg; dextrose, hydrous 5 g in water for injection; sodium metabisulfite added 50 mg. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. 269 mOsmol/liter (calc.) pH 2.5 to 4.5 Single-dose container . Discard unused portion . For intravenous use only. Recommended Dosage: See Prescribing Information. Warning: contains sulfites. Drug additives should not be made to this solution. Sterile, nonpyrogenic. Use only if solution is clear and container is undamaged. Not made with natural rubber latex. Rx only 5 OTHER MADE IN GERMANY Hospira Distributed by Hospira, Inc., Lake Forest, IL 60045 USA 12726-02 PRINCIPAL DISPLAY PANEL - 250 mL Bag Label-12726-02","PRINCIPAL DISPLAY PANEL - 250 mL Bag Label -13445-01 TO OPEN — TEAR AT NOTCH Each 100 mL contains dopamine hydrochloride 320mg; dextrose, hydrous 5 g in water for injection; sodium metabisulfite added 50 mg. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. 286 mOsmol/liter (calc.) pH 2.5 to 4.5 Single-dose container. Discard unused portion. For intravenous use only. Recommended Dosage: See Prescribing Information. WARNING: CONTAINS SULFITES. Drug additives should not be made to this solution. The overwrap is a moisture and oxygen barrier. Do not remove unit from overwrap until ready for use. Visually inspect overwrap for tears or holes. Discard unit if overwrap is damaged or if solution is darker than slightly yellow or discolored in any other way. Use unit promptly when overwrap is opened. Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. Not made with natural rubber latex. Rx only 7 OTHER 250 mL NDC 0409-1858-01 DOPAMINE HCl in 5% Dextrose Injection, USP 800 mg/250 mL (3,200 mcg/mL) Single-dose container 13445-01 Hospira Distributed by Hospira, Inc., Lake Forest, IL 60045 USA PRINCIPAL DISPLAY PANEL - 250 mL Bag Label -13445-01","PRINCIPAL DISPLAY PANEL - 250 mL Bag Label-12727-02 250 mL NDC 0409-1858-01 DOPAMINE HCl in 5% Dextrose Injection, USP 800 mg/250 mL (3,200 mcg/mL) Each 100 mL contains dopamine hydrochloride 320 mg; dextrose, hydrous 5 g in water for injection; sodium metabisulfite added 50 mg. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. 286 mOsmol/liter (calc.) pH 2.5 to 4.5 Single-dose container. Discard unused portion . For intravenous use only. Recommended Dosage : See Prescribing Information. Warning: contains sulfites Drug additives should not be made to this solution. Sterile, nonpyrogenic. Use only if solution is clear and container is undamaged. Not made with natural rubber latex . Rx only 5 OTHER MADE IN GERMANY Hospira Distributed by Hospira, Inc., Lake Forest, IL 60045 USA 12727-02 PRINCIPAL DISPLAY PANEL - 250 mL Bag Label-12727-02"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Long term animal studies have not been performed to evaluate the carcinogenic potential of dopamine. Mutagenesis Dopamine HCl at doses approaching maximal solubility showed no clear genotoxic potential in the Ames test. Although there was a reproducible dose-dependent increase in the number of revertant colonies with strains TA100 and TA98, both with and without metabolic activation, the small increase was considered inconclusive evidence of mutagenicity. In the L5178Y TK +/- mouse lymphoma assay, dopamine HCl at the highest concentrations used of 750 mcg/mL without metabolic activation, and 3,000 mcg/mL with activation, was toxic and associated with increases in mutant frequencies when compared to untreated and solvent controls; at the lower concentrations no increases over controls were noted. No clear evidence of clastogenic potential was reported in the in vivo mouse or male rat bone marrow micronucleus test when the animals were treated intravenously with up to 224 mg/kg and 30 mg/kg of dopamine HCl, respectively."]},"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Halogenated Anesthetics","severity":"major","mechanism":"Increase cardiac autonomic irritability and sensitization of the myocardium to dopamine","management":"Monitor cardiac rhythm","clinicalEffect":"Ventricular arrhythmias and hypertension"},{"drug":"MAO Inhibitors","severity":"major","mechanism":"Prolongs and potentiates the effect of dopamine by inhibiting monoamine oxidase","management":"Reduce the recommended starting dosage to no greater than one-tenth (1/10) of the recommended dose in patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of Dopamine HCl in Dextrose Injection","clinicalEffect":"Severe hypertension and cardiac arrhythmia"},{"drug":"Tricyclic Antidepressants","severity":"moderate","mechanism":"Potentiates the cardiovascular effects of dopamine","management":"Monitor blood pressure","clinicalEffect":"Hypertension"},{"drug":"Vasopressors","severity":"major","mechanism":"Potentiates the hypertensive effects of dopamine","management":"Monitor blood pressure","clinicalEffect":"Severe hypertension"}],"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1557","moleculeType":"Small molecule","molecularWeight":"189.64"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DOPAMINE HYDROCHLORIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:57:51.467601+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:58:39.440769+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:57:56.707729+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DOPAMINE HYDROCHLORIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:57:56.999956+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:57:50.294560+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:58:27.897377+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:57:50.294584+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Beta-1 adrenergic receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:57:58.610675+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:58:18.136831+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1557/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:57:58.279570+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA018826","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:57:50.294587+00:00"}},"_dailymed":{"setId":"cb97d4a0-89ed-407c-a763-209386b6f75c","title":"DOPAMINE HYDROCHLORIDE AND DEXTROSE (DOPAMINE HYDROCHLORIDE) INJECTION, SOLUTION [BAXTER HEALTHCARE CORPORATION]"},"aiSummary":"Dopamine Hydrochloride is a marketed drug primarily indicated for improving hemodynamic status in distributive shock. Its key strength lies in its established use and the protection of its key composition patent, which expires in 2028. The primary risk is the potential increase in competition as the patent expiration approaches.","_scrapedAt":"2026-03-28T00:38:01.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T01:58:39.440882+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"dopamine-hydrochloride-improving-hemodynamic-status-i","name":"Improving hemodynamic status in distributive shock","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients in distributive shock","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients in distributive shock","diagnosticRequired":null,"brandNameForIndication":""},{"id":"dopamine-hydrochloride-improving-hemodynamic-status-i","name":"Improving hemodynamic status in shock due to reduced cardiac output","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients in shock due to reduced cardiac output","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients in shock due to reduced cardiac output","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT05241041","phase":"NA","title":"Effects of Positive Psychological Group Psychotherapy and Auricular Acupressure on Withdrawal Symptoms","status":"COMPLETED","sponsor":"Inha University Hospital","startDate":"2021-09-13","conditions":"Gambling","enrollment":198},{"nctId":"NCT03648905","phase":"","title":"Clinical Laboratory Evaluation of Chronic Autonomic Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2018-09-06","conditions":"Parkinson's Disease, Multiple System Atrophy, Autonomic Failure","enrollment":89},{"nctId":"NCT00024622","phase":"","title":"PET Scanning in Parkinson s Disease","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2002-03-15","conditions":"Schizophrenia, Parkinson's Disease","enrollment":502},{"nctId":"NCT00004847","phase":"PHASE1","title":"Diagnosis of Pheochromocytoma","status":"RECRUITING","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2000-03-22","conditions":"Pheochromocytoma, Endocrine Disease, Endocrine Diseases","enrollment":3000},{"nctId":"NCT07492160","phase":"PHASE2","title":"Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","status":"RECRUITING","sponsor":"Maimonides Medical Center","startDate":"2026-03-16","conditions":"Pregnancy, Abortion","enrollment":348},{"nctId":"NCT07484217","phase":"PHASE3","title":"Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2026-02-23","conditions":"Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms","enrollment":508},{"nctId":"NCT05909267","phase":"NA","title":"Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2023-07-26","conditions":"Depressive Disorder, Major","enrollment":165},{"nctId":"NCT05325502","phase":"NA","title":"Does Caffeine Facilitate Human Reward Learning Behaviors?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yu-Shiuan Lin","startDate":"2022-05-05","conditions":"Caffeine","enrollment":36},{"nctId":"NCT04732065","phase":"PHASE1","title":"ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors","status":"RECRUITING","sponsor":"Sabine Mueller, MD, PhD","startDate":"2021-08-23","conditions":"Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma","enrollment":208},{"nctId":"NCT03537794","phase":"","title":"Characterizing Dopamine Receptor Binding in Treatment Resistant Depression","status":"RECRUITING","sponsor":"Unity Health Toronto","startDate":"2025-08-22","conditions":"Treatment Resistant Depression","enrollment":45},{"nctId":"NCT04246437","phase":"PHASE1","title":"[18F]F-DOPA Imaging in Patients With Autonomic Failure","status":"RECRUITING","sponsor":"Daniel Claassen","startDate":"2020-02-04","conditions":"Autonomic Failure, Pure Autonomic Failure, Parkinson Disease","enrollment":40},{"nctId":"NCT03947216","phase":"PHASE2","title":"Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-10-23","conditions":"Parkinson Disease","enrollment":117},{"nctId":"NCT07151378","phase":"PHASE3","title":"Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-10-27","conditions":"PARKINSON DISEASE (Disorder)","enrollment":150},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":"Acute Aluminum Phosphide Poisoned Cases","enrollment":74},{"nctId":"NCT06295952","phase":"PHASE2","title":"A Study of Pasireotide in People With Prolactinoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-27","conditions":"Prolactin-Producing Pituitary Tumor","enrollment":10},{"nctId":"NCT05292794","phase":"NA","title":"Use of CereGate Therapy for Freezing of Gait in PD","status":"RECRUITING","sponsor":"CereGate Inc.","startDate":"2022-04-18","conditions":"Parkinson Disease, Freezing of Gait, Deep Brain Stimulation","enrollment":41},{"nctId":"NCT06899217","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.","status":"ACTIVE_NOT_RECRUITING","sponsor":"CinDome Pharma, Inc.","startDate":"2025-01-29","conditions":"Idiopathic Gastroparesis","enrollment":416},{"nctId":"NCT07423546","phase":"PHASE1, PHASE2","title":"A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-04-01","conditions":"SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder","enrollment":12},{"nctId":"NCT07218952","phase":"NA","title":"Radiation Therapy (RT) for Parkinson's Disease (PD)","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2026-04","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT01432821","phase":"NA","title":"Blinking and Yawning in Epilepsy: The Role of Dopamine","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2011-09","conditions":"Idiopathic Generalized Epilepsy","enrollment":31},{"nctId":"NCT07212088","phase":"PHASE1","title":"Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"iCamuno Biotherapeutics Ltd.","startDate":"2026-02-28","conditions":"Parkinson Disease","enrollment":12},{"nctId":"NCT06086366","phase":"","title":"Presynaptic Imaging in Major Depressive Episodes After COVID-19","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-08-22","conditions":"Long COVID, Major Depressive Disorder, Major Depressive Episode","enrollment":90},{"nctId":"NCT07404813","phase":"NA","title":"The Effect of Family Member Voices on Dopamine, Serotonin Levels, and Pain in Patients in Intensive Care Units","status":"ENROLLING_BY_INVITATION","sponsor":"Zeliha CENGİZ","startDate":"2025-02-20","conditions":"Patient Engagement, Intensive Care (ICU), Family Members' Voices","enrollment":78},{"nctId":"NCT07402928","phase":"","title":"Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease","status":"RECRUITING","sponsor":"Danish Research Centre for Magnetic Resonance","startDate":"2025-06-02","conditions":"Healthy, Parkinson, Medication Administration","enrollment":140},{"nctId":"NCT05972044","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2023-07-06","conditions":"ADHD","enrollment":516},{"nctId":"NCT07322133","phase":"PHASE4","title":"Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2026-06-01","conditions":"Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN), Hypoxemic Respiratory Failure","enrollment":30},{"nctId":"NCT05110157","phase":"PHASE3","title":"Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2021-11-29","conditions":"Schizophrenia","enrollment":442},{"nctId":"NCT05824767","phase":"PHASE4","title":"Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2023-04-17","conditions":"Septic Shock, Vasodilatory Shock","enrollment":40},{"nctId":"NCT07386080","phase":"PHASE4","title":"Carbergoline for Antipsychotic Induced Hyperprolactinemia.","status":"NOT_YET_RECRUITING","sponsor":"Zealand University Hospital","startDate":"2026-05-01","conditions":"Scizophrenia","enrollment":146},{"nctId":"NCT05890911","phase":"","title":"The Meaning of Dopaminergic Pathway in Sleep Breathing Disorders.","status":"ENROLLING_BY_INVITATION","sponsor":"Wroclaw Medical University","startDate":"2023-06-01","conditions":"Sleep Apnea, Sleep-Disordered Breathing","enrollment":100},{"nctId":"NCT05676827","phase":"","title":"Pain, Central Sensitization and Psychoemotional State in Patients With Chronic Masticatory Muscle Pain","status":"ENROLLING_BY_INVITATION","sponsor":"Wroclaw Medical University","startDate":"2023-09-01","conditions":"TMD, Masticatory Muscle Pain","enrollment":102},{"nctId":"NCT06484075","phase":"PHASE1, PHASE2","title":"Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms","status":"RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2024-11-21","conditions":"Healthy Volunteers, Alcohol Use Disorder (AUD)","enrollment":180},{"nctId":"NCT01239550","phase":"NA","title":"Insulin Detemir in Obesity Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2011-04","conditions":"Diabetes, Obesity","enrollment":240},{"nctId":"NCT07313176","phase":"","title":"Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease","status":"RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2026-01","conditions":"Advanced Parkinson Disease","enrollment":215},{"nctId":"NCT05043103","phase":"","title":"Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2021-07-06","conditions":"Advanced Parkinson Disease","enrollment":312},{"nctId":"NCT06785298","phase":"PHASE2, PHASE3","title":"Fexofenadine as Adjuvant Therapy in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-10","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT00942981","phase":"","title":"Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2009-11-13","conditions":"Schizoaffective Disorder, Schizophrenia","enrollment":283},{"nctId":"NCT03190954","phase":"EARLY_PHASE1","title":"Brain Dopaminergic Signaling in Opioid Use Disorders","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2017-08-17","conditions":"Normal Physiology, Opioid Use Disorders","enrollment":153},{"nctId":"NCT03778944","phase":"NA","title":"Enhancing Renal Graft Function During Donor Anesthesia","status":"RECRUITING","sponsor":"Nazmy Edward Seif","startDate":"2018-12-20","conditions":"Renal Failure Chronic, Transplant;Failure,Kidney, Anesthesia","enrollment":60},{"nctId":"NCT01626885","phase":"PHASE2, PHASE3","title":"A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":42},{"nctId":"NCT01626859","phase":"PHASE2, PHASE3","title":"A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":38},{"nctId":"NCT02220309","phase":"","title":"Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-08-11","conditions":"Anxiety, Depression","enrollment":167},{"nctId":"NCT01626872","phase":"PHASE2, PHASE3","title":"Long-Term Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-09","conditions":"Schizophrenia","enrollment":254},{"nctId":"NCT01625897","phase":"PHASE2, PHASE3","title":"A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":125},{"nctId":"NCT06360419","phase":"PHASE3","title":"Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2024-03-18","conditions":"Major Depressive Disorder","enrollment":346},{"nctId":"NCT00862992","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-04","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT01625000","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":512},{"nctId":"NCT05318924","phase":"PHASE1, PHASE2","title":"Effects of Ghrelin Administration on Dopamine and Effort","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2022-02-21","conditions":"Major Depressive Disorder","enrollment":26},{"nctId":"NCT02038608","phase":"NA","title":"Compensatory Mechanisms in Parkinson Disease (PD)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-12","conditions":"Parkinson's Disease","enrollment":49},{"nctId":"NCT06977308","phase":"PHASE1","title":"A Multimodal Imaging Study of Dopamine in Early Psychosis","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-03-01","conditions":"Clinical High Risk for Psychosis (CHR)","enrollment":115},{"nctId":"NCT05832151","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis","status":"COMPLETED","sponsor":"CinDome Pharma, Inc.","startDate":"2023-03-27","conditions":"Diabetic Gastroparesis","enrollment":382},{"nctId":"NCT05009992","phase":"PHASE2","title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-10-20","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma","enrollment":360},{"nctId":"NCT05635409","phase":"PHASE1","title":"A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Region Skane","startDate":"2022-11-30","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT07074002","phase":"PHASE2","title":"Proof of Concept Study on BP1.4979 Effect on Essential Tremor","status":"RECRUITING","sponsor":"Bioprojet","startDate":"2025-09-17","conditions":"Essential Tremor","enrollment":50},{"nctId":"NCT07229664","phase":"PHASE2, PHASE3","title":"Vinpocetine in Patients With Parkinsonian Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-10","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT07273526","phase":"NA","title":"Adrenaline V/s Dopamine in Fuid Refractory Septic Shock","status":"RECRUITING","sponsor":"Laiba Qamar","startDate":"2025-06-01","conditions":"Fluid Refractory Septic Shock, Septic Shock","enrollment":90},{"nctId":"NCT07267065","phase":"PHASE1","title":"AAV2-hAADC for Parkinson's Disease (PDCS-01)","status":"NOT_YET_RECRUITING","sponsor":"Krzysztof Bankiewicz","startDate":"2026-02-01","conditions":"Parkinson's Disease (PD), Early Onset Parkinson Disease","enrollment":9},{"nctId":"NCT07213219","phase":"NA","title":"PET-MRI of Reward System in Parkinson's Disease With RBD","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2026-01-01","conditions":"Parkinson's Disease (PD)","enrollment":44},{"nctId":"NCT07252752","phase":"NA","title":"Dopamine and Insulin in Psychosis","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Vienna","startDate":"2026-01-01","conditions":"First Episode Psychosis (FEP)","enrollment":46},{"nctId":"NCT06878976","phase":"PHASE3","title":"Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"Axsome Therapeutics, Inc.","startDate":"2025-02-20","conditions":"Binge-Eating Disorder","enrollment":300},{"nctId":"NCT05615220","phase":"PHASE3","title":"Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults","status":"COMPLETED","sponsor":"Emalex Biosciences Inc.","startDate":"2023-01-31","conditions":"Tourette Disorder","enrollment":216},{"nctId":"NCT06568367","phase":"PHASE3","title":"Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2024-08-01","conditions":"Excessive Sleepiness, Shift-work Disorder","enrollment":520},{"nctId":"NCT04768647","phase":"PHASE1, PHASE2","title":"Vestibulopathy as a Cause of Imbalance in Parkinson","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2021-05-28","conditions":"Parkinson's Disease","enrollment":60},{"nctId":"NCT03525002","phase":"PHASE2","title":"Dopamine Action on Metabolism in Relation to Genotype","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2018-05-03","conditions":"Obesity","enrollment":120},{"nctId":"NCT06413433","phase":"PHASE3","title":"Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2024-04-26","conditions":"Binge-Eating Disorder","enrollment":450},{"nctId":"NCT07238465","phase":"PHASE3","title":"Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12","conditions":"Down Syndrome, Autonomic Dysfunction","enrollment":200},{"nctId":"NCT06052787","phase":"PHASE3","title":"Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-09-01","conditions":"Traumatic Brain Injury","enrollment":150},{"nctId":"NCT07072910","phase":"PHASE2","title":"Cabergoline for Episodic Migraine","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-12","conditions":"Migraine","enrollment":150},{"nctId":"NCT03161652","phase":"PHASE2","title":"Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema","status":"RECRUITING","sponsor":"Carmen Clapp","startDate":"2017-05-24","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":120},{"nctId":"NCT04265209","phase":"PHASE3","title":"[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2021-12-01","conditions":"Parkinson Disease, Essential Tremor","enrollment":152},{"nctId":"NCT06261905","phase":"PHASE1","title":"Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System","status":"COMPLETED","sponsor":"Yale University","startDate":"2024-03-13","conditions":"Opioid Use Disorder","enrollment":5},{"nctId":"NCT06179108","phase":"PHASE2","title":"Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"LB Pharmaceuticals Inc.","startDate":"2023-11-29","conditions":"Schizophrenia","enrollment":359},{"nctId":"NCT05060549","phase":"PHASE4","title":"Dopamine D3 Receptor Occupancy in Bipolar Depression","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-01-06","conditions":"Bipolar Depression","enrollment":8},{"nctId":"NCT04457310","phase":"PHASE2","title":"A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-03-02","conditions":"Early Course Schizophrenia Spectrum Disorder","enrollment":112},{"nctId":"NCT07215884","phase":"PHASE1","title":"Dopamine and Sensorimotor Function in Stuttering","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-30","conditions":"Stuttering, Adult","enrollment":40},{"nctId":"NCT07214285","phase":"PHASE1, PHASE2","title":"Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine)","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2025-10-01","conditions":"Parkinson Disease","enrollment":1},{"nctId":"NCT07047404","phase":"PHASE2","title":"Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation","status":"RECRUITING","sponsor":"Bioprojet","startDate":"2025-09-15","conditions":"Premature (Early) Ejaculation","enrollment":60},{"nctId":"NCT06029673","phase":"PHASE2","title":"Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss","status":"COMPLETED","sponsor":"Stanford University","startDate":"2024-02-07","conditions":"Lactation Suppressed","enrollment":69},{"nctId":"NCT06611423","phase":"PHASE1","title":"AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Heart Failure With Reduced Ejection Fraction (HFrEF), Renal Impairment","enrollment":10},{"nctId":"NCT07045935","phase":"PHASE4","title":"Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-09-16","conditions":"Prolactinoma","enrollment":60},{"nctId":"NCT02260570","phase":"EARLY_PHASE1","title":"Remediation of Impaired Self-Regulation in Patients With Mild TBI","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2015-08-01","conditions":"Mild Traumatic Brain Injury","enrollment":55},{"nctId":"NCT05103618","phase":"PHASE2","title":"Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA","status":"WITHDRAWN","sponsor":"Andrew Newberg","startDate":"2021-07-08","conditions":"Parkinson Disease, Idiopathic Parkinson Disease","enrollment":""},{"nctId":"NCT06387732","phase":"NA","title":"Mechanisms Underlying Antidepressant Effects of Physical Activity","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-04-01","conditions":"Depression","enrollment":250},{"nctId":"NCT07175948","phase":"","title":"Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children Hospital","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-06-01","conditions":"Myocarditis, Myocarditis Acute","enrollment":100},{"nctId":"NCT07173738","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2018-06-11","conditions":"Pulmonary Arterial Hypertension","enrollment":44},{"nctId":"NCT06422208","phase":"PHASE1","title":"Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Penelope J. Hallett, Ph.D.","startDate":"2024-08-07","conditions":"Parkinson Disease","enrollment":6},{"nctId":"NCT06726785","phase":"","title":"Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment","status":"RECRUITING","sponsor":"HBC Immunology Inc","startDate":"2025-07-01","conditions":"Restless Leg Syndrome (RLS)","enrollment":50},{"nctId":"NCT07001150","phase":"PHASE2","title":"Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-05-10","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT06740812","phase":"PHASE4","title":"Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Nausea and Vomiting, Nausea, Vomiting","enrollment":212},{"nctId":"NCT05290285","phase":"NA","title":"Amino Acids in Patients With Anorexia Nervosa: Double-blind Randomized Study Versus Placebo","status":"RECRUITING","sponsor":"Villa Garda Hospital","startDate":"2022-07-01","conditions":"Anorexia Nervosa","enrollment":92},{"nctId":"NCT02379338","phase":"PHASE1","title":"Study of Radiotracer [18F]Fluortriopride ([18F]FTP) by PET/CT","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2015-01","conditions":"Healthy","enrollment":29},{"nctId":"NCT04228276","phase":"NA","title":"Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2021-02-05","conditions":"Stimulant Use Disorder, Substance-related Disorders","enrollment":30},{"nctId":"NCT04373317","phase":"PHASE4","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-24","conditions":"Parkinson's Disease Psychosis","enrollment":358},{"nctId":"NCT07139756","phase":"","title":"Deciphering the Mechanisms of Central BP Regulation in Patients With PD Associated With Orthostatic Hypotension","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2025-10-01","conditions":"Parkinson Disease, Orthostatic Hypotension","enrollment":130},{"nctId":"NCT06021522","phase":"PHASE3","title":"A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emalex Biosciences Inc.","startDate":"2023-08-16","conditions":"Tourette Syndrome","enrollment":150},{"nctId":"NCT07112105","phase":"NA","title":"Repetitive Transcranial Magnetic Stimulation Treatment of Stimulant Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-01-01","conditions":"Stimulant Use Disorder","enrollment":106},{"nctId":"NCT07111442","phase":"NA","title":"A Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-08-30","conditions":"Renal Artery Stenosis Atherosclerotic, Secondary Hypertension Renal Arterial","enrollment":200},{"nctId":"NCT06284382","phase":"NA","title":"Interaction Between Early Trauma and Odor-induced Dopamine Release","status":"NOT_YET_RECRUITING","sponsor":"Hôpital le Vinatier","startDate":"2025-10-01","conditions":"Trauma, Psychological","enrollment":30},{"nctId":"NCT04459052","phase":"PHASE2","title":"FDOPA PET and Nutritional Support in Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2020-04-30","conditions":"Parkinson Disease, Idiopathic Parkinson Disease","enrollment":50},{"nctId":"NCT06875765","phase":"NA","title":"Long-term Longitudinal Imaging of Presynaptic Terminals in PD","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-07-16","conditions":"Parkinson Disease","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"administration":{"route":"Intravenous"},"crossReferences":{"chemblId":"CHEMBL1557"},"_approvalHistory":[{"date":"20020620","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"20010822","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"20120615","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19991123","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19980327","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19950830","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19940207","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19911202","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19891207","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19881115","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"20170721","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"20130521","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"20070619","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19870327","type":"ORIG","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"20120313","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"20010417","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19960207","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19940929","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19901109","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"20201211","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"19890728","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA019615"},{"date":"20180411","type":"ORIG","sponsor":"HIKMA INTL PHARMS","applicationNumber":"ANDA207707"},{"date":"20241105","type":"SUPPL","sponsor":"HIKMA INTL PHARMS","applicationNumber":"ANDA207707"},{"date":"19870813","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"20210430","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"20140514","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"20250604","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"20010410","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19861029","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19830930","type":"ORIG","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19950817","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19981116","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19860401","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19940614","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19980408","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19840918","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19911231","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19950414","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19840104","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19901115","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19840104","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19900725","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"20131216","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"20021105","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19990605","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19860924","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19940707","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19970907","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19840918","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19920507","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19950803","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19910718","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19840627","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"19960626","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018826"},{"date":"20000107","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19981209","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19940224","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19920131","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"20010322","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19880307","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19910702","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19870720","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19960920","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19900803","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19890824","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"20140514","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"20080702","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"20230912","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"20010322","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"20000107","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19940715","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19961003","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19810519","type":"ORIG","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19930112","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"20021025","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19881129","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19961022","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19910614","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19870922","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19951102","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19910702","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"},{"date":"19840910","type":"SUPPL","sponsor":"HOSPIRA","applicationNumber":"NDA018132"}],"publicationCount":368,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"DOPAMINE HYDROCHLORIDE","genericName":"DOPAMINE HYDROCHLORIDE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1974","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1974-02-25T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":"INTROPIN","application_number":"NDA017395"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1981-05-19T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"NDA018132"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1983-06-28T00:00:00.000Z","mah":"TELIGENT","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"NDA018656"},{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"1983-09-30T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":"NDA018826"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1985-10-23T00:00:00.000Z","mah":"IGI LABS INC","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070091"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1985-10-23T00:00:00.000Z","mah":"IGI LABS INC","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070092"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1986-10-15T00:00:00.000Z","mah":"B BRAUN","brand_name_local":"DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER","application_number":"NDA019099"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-02-11T00:00:00.000Z","mah":"AM REGENT","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070826"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-02-11T00:00:00.000Z","mah":"AM REGENT","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070799"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-02-11T00:00:00.000Z","mah":"AM REGENT","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070820"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-03-27T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":"DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER","application_number":"NDA019615"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1991-10-23T00:00:00.000Z","mah":"TEVA PARENTERAL","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA072999"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1991-10-23T00:00:00.000Z","mah":"TEVA PARENTERAL","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA073000"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1995-08-30T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":"DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%","application_number":"NDA020542"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-05-23T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA074403"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-04-11T00:00:00.000Z","mah":"HIKMA INTL PHARMS","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA207707"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2024-05-27T00:00:00.000Z","mah":"BrePco Biopharma Limited","brand_name_local":"Neoatricon","application_number":"EMEA/H/C/006044"},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"SMITH AND NEPHEW","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070011"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"ABBOTT","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070656"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"ABBOTT","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070657"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"SMITH AND NEPHEW","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070046"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"SMITH AND NEPHEW","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070047"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"ABRAXIS PHARM","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070364"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"ABRAXIS PHARM","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070059"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"ABRAXIS PHARM","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070058"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"IGI LABS INC","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070087"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"IGI LABS INC","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070089"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"IGI LABS INC","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070090"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"IGI LABS INC","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070093"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"IGI LABS INC","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070094"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"WARNER CHILCOTT","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"NDA018138"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"ABRAXIS PHARM","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070012"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"WARNER CHILCOTT","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070558"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"ABRAXIS PHARM","brand_name_local":"DOPAMINE HYDROCHLORIDE","application_number":"ANDA070013"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neoatricon","application_number":null}],"regulatorySummaries":{"EU_EMA_approval_87433":{"country_code":"EU","agency":"EMA","entity_type":"approval","entity_id":"87433","summary_short":"EMA granted marketing authorisation for Neoatricon (DOPAMINE HYDROCHLORIDE) for treating hypotension in neonates, infants, and children under 18 years.","summary_long":"The European Medicines Agency (EMA) granted marketing authorisation for Neoatricon (DOPAMINE HYDROCHLORIDE) on 27 May 2024. This authorisation allows BrePco Biopharma Limited to market the product in the European Union for the treatment of hypotension in haemodynamically unstable neonates, infants, and children under 18 years. The product will be available under the brand name Neoatricon.","key_points":["Marketing authorisation granted for Neoatricon (DOPAMINE HYDROCHLORIDE) by EMA on 27 May 2024.","Indication approved: treatment of hypotension in haemodynamically unstable neonates, infants, and children under 18 years.","Marketing authorisation holder: BrePco Biopharma Limited."],"citations":[{"source":"https://www.ema.europa.eu/en/medicines/human/EPAR/neoatricon"}],"generated_at":"2026-05-18T09:19:29.576Z"}},"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T01:58:39.440882+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}